Translation of SOX10 3' untranslated region causes a complex severe neurocristopathy by generation of a deleterious functional domain.

Peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg syndrome and Hirschsprung disease (PCWH) is a complex neurocristopathy caused by SOX10 mutations. Most PCWH-associated SOX10 mutations result in premature termination codons (PTCs), for which the molecular mechanism has recently been delineated. However, the first mutation reported to cause PCWH was a disruption of the native stop codon that by conceptual translation extends the protein into the 3' untranslated region (3'-UTR) for an additional 82 residues. In this study, we sought to determine the currently unknown molecular pathology for the SOX10 extension mutation using in vitro functional assays. Despite the wild-type SOX10 coding sequence remaining intact, the extension mutation led to severely diminished transcription and DNA-binding activities. Nevertheless, it showed no dominant-negative interference with wild-type SOX10 in vitro. Within the 82-amino acid tail, an 11-amino acid region (termed the WR domain) was responsible primarily for the deleterious properties of the extension. The WR domain, presumably forming an alpha-helix structure, inhibited SOX10 transcription activities if inserted in the carboxyl-terminal half of the protein. The WR domain can also affect other transcription factors with a graded effect when fused to the carboxyl termini, suggesting that it probably elicits a toxic functional activity. Together, molecular pathology for the SOX10 extension mutation is distinct from that of more common PTC mutations. Failure to properly terminate SOX10 translation causes the generation of a deleterious functional domain that occurs because of translation of the normal 3'-UTR; the mutant fusion protein causes a severe neurological disease.

[1]  M. Wegner,et al.  Prolonged Sox4 Expression in Oligodendrocytes Interferes with Normal Myelination in the Central Nervous System , 2007, Molecular and Cellular Biology.

[2]  T. Shimotake,et al.  Neuroglial disorders of central and peripheral nervous systems in a patient with Hirschsprung's disease carrying allelic SOX10 truncating mutation. , 2007, Journal of pediatric surgery.

[3]  M. Wegner,et al.  From stem cells to neurons and glia: a Soxist's view of neural development , 2005, Trends in Neurosciences.

[4]  J. Lupski,et al.  Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants. , 2005, American journal of human genetics.

[5]  J. Lupski,et al.  Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations , 2004, Nature Genetics.

[6]  P. Tam,et al.  Analysis of SOX10 mutations identified in Waardenburg‐Hirschsprung patients: Differential effects on target gene regulation , 2003, Journal of cellular biochemistry.

[7]  Ron D. Appel,et al.  ExPASy: the proteomics server for in-depth protein knowledge and analysis , 2003, Nucleic Acids Res..

[8]  K. Karplus,et al.  Hidden Markov models that use predicted local structure for fold recognition: Alphabets of backbone geometry , 2003, Proteins.

[9]  J. Lupski,et al.  Congenital hypomyelinating neuropathy, central dysmyelination, and Waardenburg–Hirschsprung disease: Phenotypes linked by SOX10 mutation , 2002, Annals of neurology.

[10]  M. Wegner,et al.  Sox10 Is an Active Nucleocytoplasmic Shuttle Protein, and Shuttling Is Crucial for Sox10-Mediated Transactivation , 2002, Molecular and Cellular Biology.

[11]  I. Verma,et al.  SOX10 mutations in chronic intestinal pseudo-obstruction suggest a complex physiopathological mechanism , 2002, Human Genetics.

[12]  O. Dubourg,et al.  Human Connexin 32, a gap junction protein altered in the X-linked form of Charcot-Marie-Tooth disease, is directly regulated by the transcription factor SOX10. , 2001, Human molecular genetics.

[13]  P. Tam,et al.  Novel mutations of SOX10 suggest a dominant negative role in Waardenburg-Shah syndrome , 2001, Journal of medical genetics.

[14]  C. Lacroix,et al.  Peripheral neuropathy with hypomyelination, chronic intestinal pseudo‐obstruction and deafness: A developmental “neural crest syndrome” related to a SOX10 mutation , 2000, Annals of neurology.

[15]  M. Wegner,et al.  The glial transcription factor Sox10 binds to DNA both as monomer and dimer with different functional consequences. , 2000, Nucleic acids research.

[16]  A. Munnich,et al.  Neurological phenotype in Waardenburg syndrome type 4 correlates with novel SOX10 truncating mutations and expression in developing brain. , 2000, American journal of human genetics.

[17]  M. Wegner,et al.  Protein Zero Gene Expression Is Regulated by the Glial Transcription Factor Sox10 , 2000, Molecular and Cellular Biology.

[18]  J. Lupski,et al.  Myelin deficiencies in both the central and the peripheral nervous systems associated with a SOX10 mutation , 1999, Annals of neurology.

[19]  M. Wegner,et al.  Functional Analysis of Sox10 Mutations Found in Human Waardenburg-Hirschsprung Patients* , 1998, The Journal of Biological Chemistry.

[20]  Giovanni Romeo,et al.  SOX10 mutations in patients with Waardenburg-Hirschsprung disease , 1998, Nature Genetics.

[21]  M. Wegner,et al.  Sox10, a Novel Transcriptional Modulator in Glial Cells , 1998, The Journal of Neuroscience.

[22]  M. Wegner,et al.  Identification of the Nuclear Localization Signal of the POU Domain Protein Tst-1/Oct6* , 1996, The Journal of Biological Chemistry.

[23]  N. Andrews,et al.  A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. , 1991, Nucleic acids research.